America's sunscreen aisle is about to get a serious upgrade. The FDA has officially added bemotrizinol — marketed as PARSOL Shield by dsm-firmenich — to its over-the-counter sunscreen monograph, making it the first new active sunscreen ingredient permitted in the U.S. since 1999. The FDA effective date hit on Aug. 9, 2026, and major brands like Neutrogena, CeraVe, and La Roche-Posay have already announced plans to launch products containing the ingredient, with some expected on shelves as early as September or October 2026.

So what makes bemotrizinol stand out? Unlike most U.S. sunscreens that rely on a combination of filters to cover both UVA and UVB rays, bemotrizinol delivers broad-spectrum protection on its own. It's also highly photostable — meaning it doesn't break down quickly in sunlight — sits on top of the skin rather than absorbing into the bloodstream, and won't leave a white cast, a common complaint with mineral sunscreens. It's the first chemical sunscreen filter to earn the FDA's "generally recognized as safe and effective" (GRASE) designation.

Key Takeaways:

• Bemotrizinol provides single-ingredient broad-spectrum UVA + UVB protection, reducing the need for complex filter combinations
• It is GRASE-approved for adults and children as young as 6 months old — the first chemical filter cleared for infant use
• Concentrations are capped at 6% in formulations; dsm-firmenich holds 18 months of market exclusivity before other brands can follow

Why it matters: The U.S. has long lagged behind Europe and Asia in sunscreen innovation — many other countries have nearly twice as many approved UV filters. Bemotrizinol's approval signals a new era for American photoprotection, potentially paving the way for additional advanced filters and better skin cancer prevention tools for a broader range of consumers.